Back
30 May - 3 June

ASCO 2025

CHICAGO

We are excited to be at ASCO 2025 to share our latest data, and engage and learn with the scientific community, solidifying our goal to bring the promise of cell therapy to as many eligible patients as possible.

To learn more about our cell therapy abstracts and data, please visit the congress website.

Phase 1 Study of KITE-363
7003

A Phase 1 Study of KITE-363 Anti-CD19/CD20 Chimeric Antigen receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory B-Cell Lymphoma

Saurabh Dahiya et al
Friday, May 30
Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia 2:45-5:45 PM CDT
Click to view full abstract
Phase 1 Study of Bivalent CAR T-Cells in Glioblastoma (UPenn Collab)
102

*Kite collaboration
A Phase 1 Study of Intracerebroventricular Delivery of Bivalent CAR T-Cells Targeting EGFR and IL13Rα2 in Patients with Recurrent Glioblastoma

Stephen J Bagley et al
Sunday, June 1
Clinical Science Symposium – Turning “Cold” Tumors “Hot” 9:45-11:15 AM CDT
Click to view full abstract
Use of Single-Cell Transcriptomics to Study the CNS Microenvironment in SCNSL (DFCI Collab)
2020

*Kite collaboration
Using Single-Cell Transcriptomics to Reveal CD226 Upregulation and Enhancement of CD19-CAR-T Function in the Inhibitory CNS Microenvironment of Refractory CNS Lymphoma

Ulrike Gerdemann et al
Saturday, May 31
Central Nervous System Tumors 3:00-4:30 PM CDT
Click to view full abstract

CIBMTR Outcomes by Outpatient Intent
7023

Trends and Outcomes by Inpatient and Outpatient Infusion of Axi-Cel in the US for Patients with R/R LBCL

Fateeha Furqan et al
Sunday, June 1
Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia 9:00 AM-12:00 PM CDT
Click to view full abstract
CIBMTR 2L+ SCNSL
7024

Real-World Outcomes of Axi-Cel for the Treatment of R/R Secondary Central Nervous System Lymphoma (SCNSL)

Narendranath Epperla et al
Sunday, June 1
Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia 9:00 AM-12:00 PM CDT
Click to view full abstract

Prognostic Value of ctDNA Detection by PhasED-Seq After Axi-cel
15043

​Prognostic Value of Circulating Tumor DNA Detection by PhasED-Seq After Axi-Cel Therapy in Relapsed/Refractory LBCL

Brodie Miles et al
May 22, 2025
Click to view full abstract

Not an official event of the 2025 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation. Not CME-accredited.

Transforming Science Within the Community

Join us to hear how Gilead's legacy has paved the way to an innovative approach for patient-centered oncology care.​

Sunday June 1, 2025 11:30 AM – 12:30 PM CT Add event to calendar

In Exhibit Hall | Industry Expert Theater 1

Add event to calendar

MEET THE SPEAKERS

MODERATOR:

Darren Tayama, MD
Vice President
US Medical Affairs, Oncology
Gilead Sciences

Darren Tayama, MD

PANELISTS

Staci Bush, PA
Senior Director, Scientific Collaboration
US Medical Affairs, Virology
Gilead Sciences

Staci Bush, PA

Timothy Best, PhD
Senior Director
Global Medical Affairs
Kite Pharma

Timothy Best, PhD

Sabrina Meyers, PharmD
Senior Director, Head of Community Oncology Strategy
US Medical Affairs, Oncology
Gilead Sciences

Sabrina Meyers, PharmD